Long-term safety study of LUM-201 in children with growth hormone deficiency
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This trial checks the long-term safety of LUM-201 in children who have idiopathic growth hormone deficiency and already completed an earlier LUM-201 study. If you previously took LUM-201 and are allowed to continue, the study may help your care team monitor ongoing effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A parent or caregiver must sign consent, and the child must give assent if they can.
- You must have completed a previous pediatric LUM-201 study through at least the 12-month visit.
- You must be eligible to continue LUM-201 treatment based on the prior study and other trial rules.
- Your child must not have any other medical or genetic condition that the study doctor feels would add extra risk with LUM-201.
- Your child must not be on long-term medicines that affect how the body breaks down LUM-201 (CYP3A4-related medicines). Short-term (2 weeks or less) may be reviewed case-by-case.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
This study follows children who are short for their age and checks how safe and effective growth hormone is over the long term. It may help families understand expected benefits and side effects for their specific growth-related condition.
This study is watching children who are already taking somapacitan (a growth hormone injection) to see if it is safe over a long time. It collects information about growth and any side effects.
This study looks at the long-term safety of the medicine LUM-201, which helps children with growth hormone deficiency (a condition where the body doesn't make enough growth hormone, so growth is slower than normal). It is a follow-up for children who already completed the first year of the main study, to see if continuing the medicine is safe over a longer time.
This trial tests a new medicine called LUM-201 for children who haven't grown enough because their bodies don't make enough growth hormone. It aims to help kids who haven't been treated before and are still at an early stage of puberty.
This trial tests an oral medication called GS3-007a for children who have not yet reached puberty and have growth hormone deficiency. The goal is to see if it helps them grow taller.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.